TriangleDexamethasone (NCT05286814)
Dexamethasone trial for Metastatic Colorectal Cancer (Mcrc) (NCT05286814). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for people aged 18–120 with unresectable liver disease from colorectal cancer, intrahepatic cholangiocarcinoma or adrenocortical cancer after systemic chemotherapy. Permitted disease outside the liver differs by cohort.
The idea: combine liver-directed chemotherapy with immune stimulation. Surgery places a pump supplying floxuridine and dexamethasone through the liver artery. PDS01ADC injections target dead tumor tissue to deliver IL-12. Systemic chemotherapy follows: FOLFOX/FOLFIRI for colorectal cancer, GemOx/FOLFOX for cholangiocarcinoma, or GemOx for adrenal cancer. Researchers measure response.
This phase 2 study plans 70 patients. Jonathan Hernandez leads at NIH’s sole recruiting Bethesda site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.